Biochemical and Biophysical Research Communications, Vol.534, 765-772, 2021
CXCL10 encoding synNotch T cells enhance anti-tumor immune responses without systemic side effect
Modifying T cells to attack tumors using engineered chimeric receptors display powerful new therapeutic capabilities. Unfortunately, the effectiveness of therapeutic T cells is limited due to the inherent T cell responses: certain facets of endogenous response programs may be toxic, and the ability to overcome the immunosuppression in TME is deficient. Here we developed a Notch receptor based synNotch T cell platform that is able to response to target tumor cells and selectively lead to CXCL10 production. Further study showed that the administration of synNotch T cells significantly inhibited the tumor growth in a humanized murine model, accompanied by the increased infiltration of CD3(+) T cells and elevated level of CXCL10 and IFN-gamma in the tumor site. A slightly increased level of CXCL10 and limited IFN-gamma were found in the serum in mice received synNotch T cells, suggesting a high security of this treatment. Finally, we demonstrated that CXCL10 is sufficient and indispensable for the synNotch T cells induced anti-tumor effect. This study provided theoretical and experimental bases for the clinical implication of CXCL10 encoding synNotch T cells. (C) 2020 Elsevier Inc. All rights reserved.